Collaborative research agreement

During March 2016, a collaborative research agreement was signed with the aim of developing cell-processing products using the novel NKT ligand, RK, and carrying out nonclinical and clinical studies. The aim of this agreement is to develop the NKT cell-targeted cancer immunotherapy to obtain regulatory approval as Cellular and Tissue-based Product.

During July 2017, a collaborative research agreement was signed with the aim of research and development NKT cell-targeted agent for allergic diseases. The research is on novel drugs for treating allergic diseases, with inhibition of immunoglobulin E production as the mechanism of action and reduction of clinical allergic symptoms accompanied.

Joint application of patent

During April 2016, RIKEN and AMBICION jointly applied for a patent covering efficient NKT cell activation.

About RIKEN

RIKEN is Japan's largest comprehensive research institution renowned for high-quality research in a diverse range of scientific disciplines. Founded in 1917 as a private research foundation in Tokyo, RIKEN has grown rapidly in size and scope, today encompassing a network of world-class research centers and institutes across Japan. For more details, please visit http://www.riken.jp/en/.